| Similar Articles |
 |
The Motley Fool September 5, 2006 Brian Gorman |
Bayer Rising? Bayer still has some hoops to jump through before it's in tip-top shape, but the company has some tantalizing opportunities. Investors, it's not too early to put the German conglomerate on the watch list.  |
The Motley Fool March 27, 2006 Rich Smith |
Bayer Prescribes Itself a Buyout Bayer's bid for Schering trumped an earlier $17.5 billion offer from yet another German powerhouse, Merck KGaA. Why would Bayer pay so much for Schering? Investors, take note.  |
The Motley Fool August 29, 2006 S.J. Caplan |
Bayer's Crop Headache The company's second-quarter earnings are up while crops drag. Investors, take note.  |
IndustryWeek September 1, 2002 John S. McClenahen |
Bayer's Formula: Two Sites Both Research Triangle Park, N.C., and Kansas City, Mo., are home to newly created Bayer CropScience's North American Operations.  |
Chemistry World September 18, 2012 Andrew Turley |
Bayer $145 million animal health deal Bayer has signed a $145 million deal to buy the US part of the animal health business at Israeli generics giant Teva.  |
The Motley Fool July 20, 2004 Brian Gorman |
Bayer Reshuffles Business Bayer, one of Germany's most venerable industrial names, is revamping its house. Seemingly in one fell swoop, the company is spinning off its Lanxess chemicals and polymers unit and buying Roche's over-the-counter-drugs business.  |
Chemistry World July 5, 2012 |
Bayer buys crop protection firm for $425m German chemical and healthcare giant Bayer has struck a deal to buy US firm AgraQuest, which makes pest control products based on 'natural' or specially bred microorganisms.  |
BusinessWeek April 8, 2010 Arlene Weintraub |
Diabetes Is No Fun, but It Can Be a Game Bayer hopes that partnering with Nintendo will make it the leader in glucose testing.  |
Chemistry World September 23, 2014 Andy Extance |
Bayer to sever polymer arm The German chemical giant has announced plans to spin off its MaterialScience business as a new company within 12 -- 18 months.  |
The Motley Fool November 30, 2006 Brian Lawler |
Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note.  |
Chemistry World August 24, 2009 Sarah Houlton |
Indian court dismisses Bayer's patent law case Bayer has failed in its attempt to stop Indian regulators giving marketing authorization to a generic version of its kidney cancer drug Nexavar (sorafenib), despite its 20 year patent having only been granted last year.  |
Chemistry World September 2, 2009 Helen Carmichael |
Bayer bows to safety concerns One year after an explosion that led to two fatalities, Bayer CropScience is to eliminate 80 per cent of its methyl isocyanate stockpile at its Institute, West Virginia site.  |
The Motley Fool November 29, 2004 Brian Gorman |
Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year.  |
The Motley Fool March 3, 2005 Brian Gorman |
Bayer Heals Itself The latest earnings report suggests things are looking up -- and drug development may soon yield more good news for investors.  |